An observational study in Japan found that anifrolumab, a new treatment targeting the interferon pathway, effectively improved disease activity and reduced glucocorticoid (GC) doses among patients with systemic lupus erythematosus (SLE). The study included patients who failed to achieve Lupus Low Disease Activity State (LLDAS) and those who experienced minor flares after achieving LLDAS. An overall retention rate of 89.7% for anifrolumab therapy at 26 weeks was observed, with 90.9% for non-LLDAS, 91.7% for minor flare, and 75% for patients aiming for remission with GC reduction. Adverse events mostly consisted of infections, and no serious adverse events were reported. Anifrolumab was found to decrease disease activity without increasing GC doses in patients with minor flares.
Source link
Anifrolumab May Help Prevent Organ Damage in Patients With Systemic Lupus Erythematosus
